Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675450 | 1.00 | PTGS2 (0.71) | PTGS2PTGS1ALOX5TTRCYP19A1 | |
| SCHEMBL4258531 | 0.85 | PTPN1 (0.58) | PTGS2PTGS1TTRAPPMAOB | |
| SCHEMBL4258538 | 0.85 | PTPN1 (0.58) | PTGS2PTGS1TTRAPPMAOB | |
| SCHEMBL12644210 | 0.84 | KMT2A (0.55) | PTGS2PTGS1ALOX5TTRMAPT | |
| SCHEMBL18130111 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1CYP19A1APPNPC1 | |
| SCHEMBL9828020 | 0.83 | ALDH1A1 (0.63) | PTGS2PTGS1CYP19A1APPNPC1 | |
| SCHEMBL9828022 | 0.83 | ALDH1A1 (0.63) | PTGS2PTGS1CYP19A1APPNPC1 | |
| SCHEMBL18130109 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1CYP19A1APPNPC1 | |
| SCHEMBL3675266 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1ALOX5TTRCYP19A1 | |
| SCHEMBL3675268 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1ALOX5TTRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4425628-B2 | — | — | 2010-03-03 | — | — | JP | claimed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | claimed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | claimed |
| JP-2005505519-A | — | — | 2005-02-24 | — | — | JP | claimed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106014-A1 | Methods for treating diabetes | ALOX5, ALOX15, ALOX15B | PTGS2 60/4885PTGS1 89/4885ALOX5 1/4885 |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | PTGS2 181/4885PTGS1 183/4885ALOX5 131/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | PTGS2 181/4885PTGS1 183/4885ALOX5 131/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | PTGS2 181/4885PTGS1 183/4885ALOX5 131/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | PTGS2 181/4885PTGS1 183/4885ALOX5 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.